MedPath

The explorative clinical trial of a medicine for treatment of CIN (Cervical Intraepithelial Neoplasia) using lactobacillus to HPV16 positive CIN 2.

Phase 2
Conditions
Cervical Intraepithelial Neoplasia 2 (CIN2)
Registration Number
JPRN-UMIN000012229
Lead Sponsor
The University of Tokyo Hospital Department of Obstetrics & Gynecology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) Person who has obviously received prohibition of using together medicine (treatment) that causes person and immune suppression that has disease that abnormality is found in immune function 2) patients of SCC in cervical cytology. 3) whom hope for laser ablation or conization of the cervix 4) patients with serious acute illness 5) patients that there are previous histories of hypersensitivity in lactobacillus content food (yogurt etc.) and preparation of lactobacillus 6) patients who has allergy for milk 7) pregnant or expected to be pregnant 8) breast feeding mother 9) whom administered other trial drugs within three months before initiation of this trial study 10) whom administered this medicine 11) whom the investigator think inappropriate as a candidate.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical efficacy and safety
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath